冠心病患者血浆长链非编码RNA-Ang362的表达与预后关系研究
|
摘要
目的:探讨冠心病患者长链非编码RNA(lncRNA)-Ang362的表达及其与患者预后的相关性。方法:随机选取2015年1月到2016年6月,于新疆医科大学第一附属医院心脏中心接受冠状动脉造影患者120例,其中对照组20例和冠心病组100例,冠心病组中包括稳定性冠心病组60例,急性冠状动脉综合征组40例。收集患者年龄、性别等基本临床特征,以实时定量PCR检测患者血浆lnc-Ang362表达,以SYNTAX评分系统评估患者冠心病严重程度,对冠心病患者进行平均26.9个月的随访,记录患者心肌梗死、血运重建等主要心脏不良事件的发生情况。结果:CAD患者的体质量指数、吸烟史、高血压和血脂异常的比例较对照组明显升高(P<0.05);lnc-Ang362在冠心病患者血浆中的表达较对照组明显升高(P<0.05);血浆lnc-Ang362水平与患者SYNTAX评分正相关(r=0.562,P=0.000)。lnc-Ang362高表达的冠心病患者具有较高的主要心脏不良事件总体发生率,lnc-Ang362高表达的急性冠状动脉综合征患者血管重建发生率亦较高(P<0.05)。lnc-Ang362表达与入组的冠心病患者主要心脏不良事件总体发生率正相关(r=0.602,P=0.000)。结论:血浆lncRNA-Ang362可作为冠心病患者严重程度评价的分子标志物,并协助评估患者预后。
Objective: To investigate the expression of lncRNA-Ang362 in patients with coronary heart disease and its correlation with prognosis. Methods: 120 patients who underwent coronary angiography Heart Center, the First Affiliated Hospital of Xinjiang Medical University from January 2015 to June 2016 were randomly selected, including 20 patients in the control group and 100 patients in the coronary heart disease group. The coronary heart disease group included 60 patients in the stable coronary heart disease group and 40 patients in the coronary syndrome group. The basic clinical characteristics such as age and gender were collected. The expression of lnc-Ang362 in patients was detected by real-time quantitative PCR. The severity of coronary heart disease was evaluated by SYNTAX scoring system. The patients with coronary heart disease were followed up for an average of 26.9 months. The incidence of major cardiac adverse events such as myocardial infarction and revascularization was recorded. Results: The BMI, smoking history, hypertension and dyslipidemia of patients with CAD were significantly higher than those of the control group(P<0.05). The expression of lnc-Ang362 in plasma of patients with coronary heart disease was significantly higher than that of the control group(P<0.05). The plasma lnc-Ang362 level was positively correlated with the patient′s SYNTAX score(r=0.562, P=0.000). Patients with high expression of lnc-Ang362 had higher incidence of major cardiac adverse events, and the incidence of vascular remodeling in patients with acute coronary syndrome with high expression of lnc-Ang 362 was also higher(P<0.05). The expression of lnc-Ang362 was positively correlated with the overall incidence of major cardiac adverse events in patients with coronary heart disease(r=0.602, P=0.000). Conclusions: Plasma lncRNA-Ang 362 can be used as a molecular marker for the severity assessment of patients with coronary heart disease and to help assess the prognosis of patients.
Objective: To investigate the expression of lncRNA-Ang362 in patients with coronary heart disease and its correlation with prognosis. Methods: 120 patients who underwent coronary angiography Heart Center, the First Affiliated Hospital of Xinjiang Medical University from January 2015 to June 2016 were randomly selected, including 20 patients in the control group and 100 patients in the coronary heart disease group. The coronary heart disease group included 60 patients in the stable coronary heart disease group and 40 patients in the coronary syndrome group. The basic clinical characteristics such as age and gender were collected. The expression of lnc-Ang362 in patients was detected by real-time quantitative PCR. The severity of coronary heart disease was evaluated by SYNTAX scoring system. The patients with coronary heart disease were followed up for an average of 26.9 months. The incidence of major cardiac adverse events such as myocardial infarction and revascularization was recorded. Results: The BMI, smoking history, hypertension and dyslipidemia of patients with CAD were significantly higher than those of the control group(P<0.05). The expression of lnc-Ang362 in plasma of patients with coronary heart disease was significantly higher than that of the control group(P<0.05). The plasma lnc-Ang362 level was positively correlated with the patient′s SYNTAX score(r=0.562, P=0.000). Patients with high expression of lnc-Ang362 had higher incidence of major cardiac adverse events, and the incidence of vascular remodeling in patients with acute coronary syndrome with high expression of lnc-Ang 362 was also higher(P<0.05). The expression of lnc-Ang362 was positively correlated with the overall incidence of major cardiac adverse events in patients with coronary heart disease(r=0.602, P=0.000). Conclusions: Plasma lncRNA-Ang 362 can be used as a molecular marker for the severity assessment of patients with coronary heart disease and to help assess the prognosis of patients.
引文
[1] Dai X,Wiernek S,Evans J P,et al.Genetics of coronary artery disease and myocardial infarction[J].World J Cardiol,2016,8(1):1-23.
[2] 史雨晨,柳景华.成纤维细胞生长因子21与冠状动脉粥样硬化性心脏病关系的研究进展[J].心肺血管病杂志,2018,37(10):901-903.
[3] 杨佳伟,胡沛.Apelin-13及一氧化氮在急性冠状动脉综合征者中的水平变化及其意义[J].心肺血管病杂志,2017,36(06):444-446.
[4] Wang X,Han Y,Sabina S,et al.HDAC9 Variant Rs2107595 Modifies susceptibility to coronary artery disease and the severity of coronary atherosclerosis in a chinese han population[J].PLoS One,2016,11(8).
[5] Gao S,Wassler M,Zhang L,et al.MicroRNA-133a Regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis[J].Atherosclerosis,2014,232(1):171-179.
[6] Sun M,Kraus W L.From discovery to function:the expanding roles of long noncoding rnas in physiology and disease[J].Endocr Rev,2015,36(1):25-64.
[7] Cai Y,Yang Y,Chen X,et al.Circulating “LncPPARδ” from monocytes as a novel biomarker for coronary artery diseases[J].Medicine (Baltimore),2016,95(6).
[8] Hou J,Long H,Zhou C,et al.Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro[J].Stem Cell Res Ther,2017,8.
[9] Zhang Z,Gao W,Long Q Q,et al.Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population[J].Sci Rep,2017,7.
[10] Leung A,Trac C,Jin W,et al.Novel long non-coding RNAs are regulated by angiotensin ii in vascular smooth muscle cells[J].Circ Res,2013,113(3):266-278.
[11] 黄崚.急性心力衰竭诊断和治疗指南[J].疑难病杂志,2010,9(07):557.
[12] Huang S,Chen Z,Wu W,et al.MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie[J].Exp Ther Med,2018,15(1):633-640.
[13] Nishiguchi T,Imanishi T,Akasaka T.MicroRNAs and cardiovascular diseases[J].Biomed Res Int,2015,2015.
[14] Liu T,Zhang X,Yang Y,et al.Increased expression of the long noncoding RNA CRNDE-h indicates a poor prognosis in colorectal cancer,and is positively correlated with IRX5 mRNA expression[J].Onco Targets Ther,2016,9:1437-1448.
[15] Li H,Zhu H,Ge J.Long Noncoding RNA:recent updates in atherosclerosis[J].Int J Biol Sci,2016,12(7):898-910.
[2] 史雨晨,柳景华.成纤维细胞生长因子21与冠状动脉粥样硬化性心脏病关系的研究进展[J].心肺血管病杂志,2018,37(10):901-903.
[3] 杨佳伟,胡沛.Apelin-13及一氧化氮在急性冠状动脉综合征者中的水平变化及其意义[J].心肺血管病杂志,2017,36(06):444-446.
[4] Wang X,Han Y,Sabina S,et al.HDAC9 Variant Rs2107595 Modifies susceptibility to coronary artery disease and the severity of coronary atherosclerosis in a chinese han population[J].PLoS One,2016,11(8).
[5] Gao S,Wassler M,Zhang L,et al.MicroRNA-133a Regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis[J].Atherosclerosis,2014,232(1):171-179.
[6] Sun M,Kraus W L.From discovery to function:the expanding roles of long noncoding rnas in physiology and disease[J].Endocr Rev,2015,36(1):25-64.
[7] Cai Y,Yang Y,Chen X,et al.Circulating “LncPPARδ” from monocytes as a novel biomarker for coronary artery diseases[J].Medicine (Baltimore),2016,95(6).
[8] Hou J,Long H,Zhou C,et al.Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro[J].Stem Cell Res Ther,2017,8.
[9] Zhang Z,Gao W,Long Q Q,et al.Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population[J].Sci Rep,2017,7.
[10] Leung A,Trac C,Jin W,et al.Novel long non-coding RNAs are regulated by angiotensin ii in vascular smooth muscle cells[J].Circ Res,2013,113(3):266-278.
[11] 黄崚.急性心力衰竭诊断和治疗指南[J].疑难病杂志,2010,9(07):557.
[12] Huang S,Chen Z,Wu W,et al.MicroRNA-31 promotes arterial smooth muscle cell proliferation and migration by targeting mitofusin-2 in arteriosclerosis obliterans of the lower extremitie[J].Exp Ther Med,2018,15(1):633-640.
[13] Nishiguchi T,Imanishi T,Akasaka T.MicroRNAs and cardiovascular diseases[J].Biomed Res Int,2015,2015.
[14] Liu T,Zhang X,Yang Y,et al.Increased expression of the long noncoding RNA CRNDE-h indicates a poor prognosis in colorectal cancer,and is positively correlated with IRX5 mRNA expression[J].Onco Targets Ther,2016,9:1437-1448.
[15] Li H,Zhu H,Ge J.Long Noncoding RNA:recent updates in atherosclerosis[J].Int J Biol Sci,2016,12(7):898-910.